Subudhi et al. found that in prostate cancer patients treated with ICIs, expansion of ≥ 55 CD8 T cell clones preceded the development of grade 2–3 irAEs.122 Additionally, detection of autoantibody in the serum is another potential predictor for the occurrence of irAEs. Here, CD8A is linked to prostate cancer.